Cirrhosis Management Market Globally Expected to Drive Growth through 2027
Posted: Nov 03, 2017
Cirrhosis causes the liver to shrink and harden which makes it difficult for the blood to flow into the portal vein in the liver.The liver becomes lumpy and hard, and will start to fail. Basically the liver is a hardy organ and has the ability to regenerate damaged cells. Cirrhosis develops in the liver when factors like chronic viral infections and alcohol are present for a long period of time. When this condition happens, the liver becomes scarred and injured. Scared liver cannot function properly which ultimately results in cirrhosis. The main causes of cirrhosis are excess alcohol consumption, hepatitis B, Hepatitis C and non-alcoholic fatty liver diseases.
The appropriate method for cirrhosis management is of major importance. Thus it is expected to be the prime factor driving growth of global cirrhosis management. Increasing prevalence of disease such as non-alcoholic fatty liver diseases is fueling the global cirrhosis management market growth. Moreover, the growing geriatric population has also lead to the significant addition in the global cirrhosis management market. However the lack of low treatment rate due to absence of signs and symptoms of cirrhosis are limiting the growth of global cirrhosis management market.
Based on the treatment type, the global cirrhosis management market is segmented into treating cirrhosis causes, symptomatic treatment, treatment to avoid complications and liver transplantation. Based on disease indication, the global cirrhosis management market is segmented into alcoholic liver cirrhosis and non-alcoholic liver cirrhosis. Based on end user, the global cirrhosis management market is segmented into hospitals, ambulatory surgical centers, research institutes, dialysis centers, clinics and others.
Geographically, global cirrhosis management market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is expected to dominate global cirrhosis management market over the forecast period due to high prevalence of liver cirrhosis diseases. Western Europe is expected to be the second largest market for cirrhosis management.
Request For Report sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5045
Some of the players identified in global cirrhosis management market include B. Braun Medical Inc., Alliancells Bioscience Corporation Limited, Conatus Pharmaceuticals Inc., Stempeutics Research Pvt Ltd, Merck Sharp & Dohme Corp., Epic Research & Diagnostics, Inc., Theravance Biopharma R&D, Inc., NovaShunt AG among others
The global dry powder inhalers market can be segmented based on product type, performance level, therapy type, usage type, and region.